Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species
Open Access
- 14 July 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (7) , e009099-15
Abstract
Background: Vorinostat (SAHA) is a histone deacetylase inhibitor that has shown clinical efficacy against advanced cutaneous T-cell lymphoma (CTCL). However, only a subset of patients with CTCL (30–35%) respond to SAHA and the response is not always sustainable. Thus, understanding the mechanisms underlying evasive resistance in this cancer is an unmet medical need to improve the efficacy of current therapies. Purpose: This study aims to identify factors contributing to resistance against SAHA in CTCL and ways to mitigate it. Methods and results: In this study, we demonstrated that attenuated reactive oxygen species (ROS) induces the expression of interleukin (IL)-2Rα, one of the IL-2 receptors, which drives resistance to SAHA in CTCL. We also determined that cantharidin could overcome SAHA resistance to CTCL by blocking IL-2Rα-related signaling via ROS-dependent manner. Mechanistically, accelerated translation of IL-2Rα contributes to excessive IL-2Rα protein formation as a result of reduced ROS levels in SAHA-resistant CTCL. At the same time, amplified IL-2R signals are evidenced by strengthened interaction of IL-2Rβ with IL-2Rγ and Janus kinase/signal transducer and activator of transcription molecules, and by increased expression of protein kinase B (AKT)/mTOR and mitogen-activated protein kinase signaling. Moreover, cantharidin, an active constituent of Mylabris used in traditional Chinese medicine, markedly increased ROS levels, and thereby restrained IL-2Rα translation, resulting in suppression of downstream pathways in SAHA-resistant cells. Cantharidin is also found to synergize with SAHA and triggers SAHA-resistant cell death via IL-2R signaling both in vitro and in vivo. Conclusion: Our study uncovers a novel molecular mechanism of acquired SAHA resistance and also suggests that using cantharidin is a potential approach to overcome CTCL therapy resistance. Our findings underlie the therapeutic potential of cantharidin in treating CTCL.Keywords
Funding Information
- National Natural Science Foundation of China (82104213, 82374095)
- Shaanxi Province Key Research and Development Plan Project (2024SF-YBXM-145)
- Shaanxi Province Science and Technology Development Plan Project (2022ZDLSF05-05)
- Shaanxi Province Science Fund for Distinguished Young Scholars (2023-JC-JQ-59)
- Xi’an Jiaotong University medical “basic – clinical” fusion innovation project (YXJLRH2022038)
- Central Universities Basic Research Funds (xzy012022119)
This publication has 33 references indexed in Scilit:
- Histone deacetylase inhibitor pracinostat suppresses colorectal cancer by inducing CDK5-Drp1 signaling-mediated peripheral mitofissionJournal of Pharmaceutical Analysis, 2023
- Cutaneous T‐cell lymphoma—Focus on some problems, and some solutionsHematological Oncology, 2023
- The IL-2A receptor pathway and its role in lymphocyte differentiation and functionCytokine & Growth Factor Reviews, 2022
- A strategy of screening and binding analysis of bioactive components from traditional Chinese medicine based on surface plasmon resonance biosensorJournal of Pharmaceutical Analysis, 2021
- Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell LymphomaJournal of Investigative Dermatology, 2021
- The IL-2 – IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptorClinical Immunology, 2020
- High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective StudyClinical Lymphoma Myeloma and Leukemia, 2019
- Biology of IL-2 and its therapeutic modulation: Mechanisms and strategiesJournal of Leukocyte Biology, 2018
- Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics2018
- Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T‐cell lymphoma models: Defining molecular mechanisms of resistanceInternational Journal of Cancer, 2010